{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/BLCO/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T03:41:59.798Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7241,"canonical_name":"Bausch & Lomb Corp","cik":"0001860742","uei":null,"lei":null,"duns":null,"ticker":"BLCO"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":29,"clinical":3,"fda":1},"count":33,"timeline":[{"ts":"2026-10-13","kind":"sec.filing","form_type":"8-K","title":"8-K — Bausch & Lomb Corp — 2026-10-13","url_slug":"/sec/cik-0001860742/8-k/0000950103-26-015460","accession_number":"0000950103-26-015460","importance":35},{"ts":"2026-09-10","kind":"clinical.trial","reporter":"Bausch & Lomb Incorporated","title":"A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07717918","excerpt":"[\"Healthy\"]","importance":30},{"ts":"2026-08-21","kind":"clinical.trial","reporter":"Bausch & Lomb Incorporated","title":"BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07778888","excerpt":"[\"Dry Eye Disease\"]","importance":45},{"ts":"2026-08-12","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-08-12","url_slug":"/sec/cik-0001860742/4/0001860742-26-000096","accession_number":"0001860742-26-000096","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"8-K/A","title":"8-K/A — Bausch & Lomb Corp — 2026-08-12","url_slug":"/sec/cik-0001860742/8-k-a/0000950103-26-012223","accession_number":"0000950103-26-012223","importance":30},{"ts":"2026-08-11","kind":"sec.form144","reporter":"Munsch Frederick","title":"Officer","shares":52900,"usd_value":887885,"security_title":"Common","approx_sale_date":"2026-08-10","accession_number":"0001959173-26-005864","importance":40.177577028},{"ts":"2026-08-10","kind":"sec.filing","form_type":"144","title":"144 — Bausch & Lomb Corp — 2026-08-10","url_slug":"/sec/cik-0001860742/144/0001959173-26-005847","accession_number":"0001959173-26-005847","importance":30},{"ts":"2026-08-07","kind":"sec.insider.s","reporter":"VON ESCHENBACH ANDREW C.","title":null,"shares":6059,"price_per_share":16.58,"usd_value":100458,"security_title":"Common Shares, No Par Value","importance":35.10045822},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-08-07","url_slug":"/sec/cik-0001860742/4/0001860742-26-000091","accession_number":"0001860742-26-000091","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-08-07","url_slug":"/sec/cik-0001860742/4/0001860742-26-000093","accession_number":"0001860742-26-000093","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-08-07","url_slug":"/sec/cik-0001860742/4/0001860742-26-000094","accession_number":"0001860742-26-000094","importance":30},{"ts":"2026-08-07","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-08-07","url_slug":"/sec/cik-0001860742/4/0001860742-26-000095","accession_number":"0001860742-26-000095","importance":30},{"ts":"2026-08-06","kind":"sec.insider.s","reporter":"VON ESCHENBACH ANDREW C.","title":null,"shares":12500,"price_per_share":16.5,"usd_value":206250,"security_title":"Common Shares, No Par Value","importance":35.20625},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Bausch & Lomb Corp — 2026-08-06","url_slug":"/sec/cik-0001860742/8-k/0000950103-26-011979","accession_number":"0000950103-26-011979","importance":35},{"ts":"2026-08-05","kind":"sec.insider.f","reporter":"SAUNDERS BRENT L","title":"Chairman of the Board and CEO","shares":4231,"price_per_share":16.76,"usd_value":70912,"security_title":"Common Shares, No Par Value","importance":15.07091156},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"SAUNDERS BRENT L","title":"Chairman of the Board and CEO","shares":281879,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Eldessouky Sam","title":"EVP and CFO","shares":50335,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Bailey A Robert D","title":"EVP & Chief Legal Officer","shares":33557,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Bonnefoy Luc","title":"President, Surgical","shares":16778,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Hashad Yehia","title":"EVP of R&D and CMO","shares":20973,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Munsch Frederick","title":"SVP, Controller and CAO","shares":9091,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-08-05","kind":"sec.insider.a","reporter":"Stewart Andrew J.","title":"President, GPIC","shares":16778,"price_per_share":0,"usd_value":0,"security_title":"Common Shares, No Par Value","importance":15},{"ts":"2026-07-29","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Bausch & Lomb Corp — 2026-07-29","url_slug":"/sec/cik-0001860742/10-q/0001860742-26-000088","accession_number":"0001860742-26-000088","importance":45},{"ts":"2026-07-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Bausch & Lomb Corp — 2026-07-29","url_slug":"/sec/cik-0001860742/8-k/0001860742-26-000086","accession_number":"0001860742-26-000086","importance":35},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-06-16","url_slug":"/sec/cik-0001860742/4/0001860742-26-000084","accession_number":"0001860742-26-000084","importance":30},{"ts":"2026-06-12","kind":"sec.insider.f","reporter":"Bonnefoy Luc","title":"President, Surgical","shares":1008,"price_per_share":15.08,"usd_value":15201,"security_title":"Common Shares, No Par Value","importance":15.01520064},{"ts":"2026-06-01","kind":"sec.filing","form_type":"SD","title":"SD — Bausch & Lomb Corp — 2026-06-01","url_slug":"/sec/cik-0001860742/sd/0001860742-26-000083","accession_number":"0001860742-26-000083","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"8-K","title":"8-K — Bausch & Lomb Corp — 2026-05-20","url_slug":"/sec/cik-0001860742/8-k/0001193125-26-232712","accession_number":"0001193125-26-232712","importance":35},{"ts":"2026-05-19","kind":"fda.label","reporter":"Bausch & Lomb Incorporated","title":"Blink Triple Care Preservative Free","security_title":"POLYETHYLENE GLYCOL 400","excerpt":"Uses for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun for use as a protectant against further irritation or to relieve dryness of th","accession_number":"65e67990-78b7-4ce9-963b-6bed3a6bed07","route":"OPHTHALMIC","product_type":"HUMAN OTC DRUG","importance":30},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Bausch & Lomb Incorporated","title":"Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07168902","excerpt":"[\"Glaucoma\"]","importance":45},{"ts":"2026-04-27","kind":"sec.filing","form_type":"4","title":"4 — Bausch & Lomb Corp — 2026-04-27","url_slug":"/sec/cik-0001860742/4/0001860742-26-000058","accession_number":"0001860742-26-000058","importance":30},{"ts":"2026-04-24","kind":"sec.insider.f","reporter":"Bailey A Robert D","title":"EVP & Chief Legal Officer","shares":15806,"price_per_share":15.82,"usd_value":250051,"security_title":"Common Shares, No Par Value","importance":15.25005092},{"ts":"2026-04-24","kind":"sec.insider.f","reporter":"Stewart Andrew J.","title":"President, GPIC","shares":4216,"price_per_share":15.82,"usd_value":66697,"security_title":"Common Shares, No Par Value","importance":15.06669712}]}